Nearly half of ANCA-associated vasculitis (AAV) patients treated with rituximab developed hypogammaglobulinemia (HGG), or low blood levels of antibodies, according to a population-based Swedish study. While antibodies normally help fight infections, the occurrence of HGG was not associated with an increased risk of severe infections among rituximab-treated patients…
Discussion
Living with ANCA-associated vasculitis forces us to redefine a lot of things, including our energy, our expectations, and our sense of normal. But one of the most important and sometimes overlooked things we have to redefine is what we consider “good enough.” Because when it comes to our health…
Discussion
The ANCA-associated vasculitis Patient-Reported Outcome (AAV-PRO) questionnaire captures physical, social, emotional, and symptom-related burdens that are closely linked to difficulties in daily life but are not always reflected in physician assessments. That’s according to a study in Germany that used the German-language version of the AAV-PRO questionnaire, which had…
Becoming educated and informed about ANCA vasculitis is a good first step. Here you’ll find general information such as the diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your ANCA vasculitis journey.
There is no cure for ANCA vasculitis yet, but here you can find more information about current approved treatments, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
